GLOW (GHK-Cu + TB-500 + BPC-157)

1. 1

   Remove the lyophilized 70 mg peptide vial from the −20 °C freezer and allow it to equilibrate to room temperature for 15 to 20 minutes.

2. 2

   Sterilize the rubber septum of both the peptide vial and the bacteriostatic water vial using a fresh 70% isopropyl alcohol swab and allow them to air-dry completely.

3. 3

   Using a sterile reconstitution syringe, draw 3.0 mL of bacteriostatic water from the diluent vial.

4. 4

   Insert the needle at a slight angle and inject the 3.0 mL of bacteriostatic water slowly down the inside glass wall of the peptide vial to avoid agitation and foaming.

5. 5

   Gently swirl and roll the vial between your palms until the powder is fully dissolved into a clear, characteristic light-blue solution; never shake vigorously.

6. 6

   Affix a research label noting the reconstitution date, total concentration (23.3 mg/mL total blend), and immediately store in the dark at 2–8 °C.

Overview

The GLOW blend is an investigational multi-peptide formulation co-lyophilized in a fixed 5:1:1 stoichiometric ratio, containing 50 mg of copper tripeptide-1 (GHK-Cu), 10 mg of the synthetic actin-sequestering fragment TB-500, and 10 mg of the pentadecapeptide BPC-157. Formulating these distinct compounds into a single multi-dose unit provides experimental convenience for exploring concurrent cellular pathways involved in tissue remodeling, angiogenic signaling, and extracellular matrix stabilization. Each constituent brings an independent mechanism to the mixture. GHK-Cu acts via copper transport to upregulate procollagen expression, modulate matrix metalloproteinases, and exhibit antioxidant activity. TB-500 mimics key regions of thymosin beta-4 to accelerate cellular migration and tissue restitution via actin sequestering, while BPC-157 stimulates the nitric oxide signaling cascade and vascular endothelial growth factor (VEGF) release to promote cytoprotection and microvascular repair. This composite blend is strictly designed for in vitro and preclinical laboratory research to evaluate coordinated regenerative signaling networks. Co-formulation in a single lyophilized vial locks the stoichiometric ratios together, which facilitates fixed-ratio trials while precluding independent dosage titration of the individual peptides. The mixture has not been clinically evaluated or approved for human therapeutic use.

1. 1.Pickart L, Vasquez-Soltero JM, Margolina A, Int J Mol Sci, 2018 — Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data
2. 2.Sikiric P et al., Curr Pharm Des, 2018 — Stable gastric pentadecapeptide BPC 157, novel therapy in gastrointestinal tract and beyond
3. 3.Sosne G et al., Expert Opin Biol Ther, 2010 — Thymosin beta 4: a novel corneal wound healing agent with multi-factorial mechanisms of action
4. 4.Chang CH et al., J Orthop Res, 2011 — The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.